Argo Drives 5.5x Increase in Connections to GO Station Growth in connections to Bradford GO Station demonstrates the power of Argo's Smart Routing(TM) system in complementing existing public transit networks and driving increased ridership GlobeNewswire October 29, 2025 TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Argo Corporation (TSXV:ARGH) (OTCQX:ARGHF) (“Argo” or the “Company”), a leader […]
(Other OTC:IDVV),(Other OTC:PINWF),(LSE:PINE),(Other OTC:CYSNF),(TSX-V:CMI),(Other OTC:KPIFF),(TSX-V:YFI),(Other OTC:AITX),(NASDAQ:COCH),(Other OTC:TAKOF),(TSX-V:FLT),(Other OTC:CCDSF),(TSX-V:CCDS),(Other OTC:BCNWF),(TSX-V:BTCW),(Other OTC:SWISF),(CNSX:SKUR.CN),(Other OTC:CYBHF),(TSX-V:CYBE),(Other OTC:BCCEF),(Other OTC:SPAIF),(CNSX:SPAI.CN),(CNSX:BAC.CN), NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the AI & Technology Virtual Investor Conference, held October 28th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS
(HKSE:00142),(OtherOTC:FPAFY), HONG KONG, Oct. 29, 2025 (GLOBE NEWSWIRE) — First Pacific Company Limited (Hong Kong: 00142, ADR: FPAFY), based in Hong Kong, focused on domestic defensive businesses in the fast-growing region of Southeast Asia, today announced that John W. Ryan, Associate Director, will present live at the dbVIC – Deutsch Bank American Depositary Receipt (ADR)
(NASDAQ:MBRX), HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with
(NASDAQ:BLTE), SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hao-Yuan Chuang, Chief Financial Officer, will present live at the dbVIC – Deutsche Bank
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin GlobeNewswire October 29, 2025 HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office
AI & Technology Virtual Investor Conference: Presentations Now Available for Online Viewing Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com GlobeNewswire October 29, 2025 NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the AI & Technology Virtual Investor Conference,
First Pacific to Present at the dbVIC – Deutsche Bank ADR Virtual Investor Conference November 4th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire October 29, 2025 HONG KONG, Oct. 29, 2025 (GLOBE NEWSWIRE) — First Pacific Company Limited (Hong Kong: 00142, ADR: FPAFY), based
Belite Bio to Present at the dbVIC – Deutsche Bank ADR Virtual Investor Conference November 4th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire October 29, 2025 SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a
GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting with the U.S. Food and Drug Administration (FDA) for the Company's lead program, GENV-HEM, a novel gene therapy for Hemophilia A with or without inhibitors (antibodies to Factor VIII).